GlycoMimetics Announces Preclinical Data Shows GMI-1271 Reverses Drug Resistance in Multiple Myeloma Models at #ASH15

GlycoMimetics, Inc.

announced today that preclinical data presented in a poster at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition, in Orlando, Florida, on its drug candidate GMI-1271 showed the compound could reverse molecular mechanisms of chemotherapy resistance seen in multiple myeloma. "The data on GMI-1271 show a promising pathway toward reducing resistance to chemotherapy and other drugs in multiple myeloma," said Helen Thackray, M.D., Vice President and Chief Medical Officer of GlycoMimetics. "We're encouraged by the potential to use a biomarker to identify a specific population of multiple myeloma patients who might benefit from this therapy, and we intend to initiate a clinical trial in Europe in mid-2016."